Your AI-Trained Oncology Knowledge Connection!

Daniel Morgensztern, MD

home / authors / daniel-morgensztern-md

Articles

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

June 16th 2025

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

March 24th 2025

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

February 10th 2025

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Clinical Applications of The Cancer Genome Atlas Project (TCGA) for Squamous Cell Lung Carcinoma

Siddhartha Devarakonda, MD;Daniel Morgensztern, MD;Ramaswamy Govindan, MD

September 16th 2013

We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings.